Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04523655 vs Laser Therapy in Diabetic Macular Edema (DEGAS)
NCT00701181Phase 2Terminated
- Sponsor
- Quark Pharmaceuticals
- Start
- Jun 2008
- Primary completion
- Jan 2011
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 8
01
Overview
A Phase 2 trial of PF-04523655 in diabetic macular edema (DME), sponsored by Quark Pharmaceuticals. Started Jun 2008; status: terminated.
02
Drugs
PF-04523655
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT00701181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00701181.